Superior efficacy with a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin-naïve Japanese patients with type 2 diabetes in a phase 3, open-label, randomized trial.
Kohei KakuEiichi ArakiYukio TanizawaBue Ross AgnerTomoyuki NishidaMattis RantheNobuya InagakiPublished in: Diabetes, obesity & metabolism (2019)
IDegLira was superior to degludec and liraglutide in terms of HbA1c reduction and superior to degludec in terms of body weight change and rates of hypoglycaemia in Japanese people with T2D.